drugset
drugset / Trial / NCT04609241

CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

NCT04609241 ↗

Phase 0 Not yet recruiting 72 enrolled Zhejiang University Yake Biotechnology Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

A study of CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

Timeline

Start
2020-11-15
Primary completion
2023-11-15
Completion
2026-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject CD79b CAR-T Cells Cell therapy — Intravenous

Indications

B-cell non-Hodgkin lymphoma acute lymphoblastic leukemia